Ignite Creation Date:
2024-05-06 @ 12:23 AM
Last Modification Date:
2024-10-26 @ 10:49 AM
Study NCT ID:
NCT01562015
Status:
COMPLETED
Last Update Posted:
2015-05-20
First Post:
2012-03-14
Brief Title:
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer NSCLC
Sponsor:
Synta Pharmaceuticals Corp
Organization:
Synta Pharmaceuticals Corp
Study Overview
Official Title:
A Single Arm Phase 2 Study of Ganetespib in Subjects With Advanced Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Gene Rearrangement ALK-Positive NSCLC
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CHIARA
Brief Summary:
Phase 2 study of subjects with ALK positive advanced NSCLC who have failed up to 3 prior therapies The study will take place globally at multiple study centers Subjects will be enrolled to receive ganetespib one time per week for three weeks followed by a rest week and will repeat this schedule until the cancer gets worse or the subject is unable to tolerate ganetespib The primary goal of the study is to determine how ganetespib is tolerated and how active it is in ALK positive NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None